Skeletal Langerhans cell histiocytosis in children: Permanent consequences and health‐related quality of life in long‐term survivors
- 9 January 2008
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (3) , 607-612
- https://doi.org/10.1002/pbc.21322
Abstract
Background: The skeleton is the most frequently involved organ in Langerhans cell histiocytosis (LCH) in children, and bone LCH generally has an excellent long‐term survival. Although permanent consequences (PC) are described in half of the survivors thus raising concerns for quality of life (QOL), the impact on quality of life has not been formally studied.Methods: A retrospective review was performed on 124 LCH patients with skeletal involvement, followed by prospective evaluation of PC and health‐related QOL using age‐appropriate validated study tools (PedsQL or SF‐36).Results: Of the 116 survivors, PC were found in 34 (29%) patients, of whom 8 had more than 1 PC. PC were significantly more frequent in multi‐system (M‐S) than in single system (S‐S) LCH (73% vs. 17%; P < 0.0001). While diabetes insipidus (65%) was the most common PC in M‐S LCH, cosmetic and orthopedic problems made up the majority of PC in S‐S LCH. The median follow‐up time was 8.5 years. 27 patients completed the PedsQL survey and 22 the SF‐36 survey. The QOL scores for LCH patients were not significantly different from healthy children in the PedsQL survey and from young adults in the SF‐36 survey. In addition, the QOL scores were very similar between patients with and without PC and between patients with M‐S and S‐S LCH.Conclusions: Children with M‐S LCH had a significantly higher risk of developing PC. Skeletal LCH did not adversely affect the quality of life of survivors, including those with PC who appeared to adapt to their disabilities and medical problems. Pediatr Blood Cancer 2008;50:607–612.Keywords
This publication has 26 references indexed in Scilit:
- Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study GroupPediatric Blood & Cancer, 2004
- The PedsQL™* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and ValidityAcademic Pediatrics, 2003
- Cognitive Outcome of Long-Term Survivors of Multisystem Langerhans Cell Histiocytosis: A Single-Institution, Cross-Sectional StudyJournal of Clinical Oncology, 2003
- Langerhans' cell histiocytosisThe Lancet, 2003
- Pattern and course of single‐system disease in Langerhans cell histiocytosis data from the DAL‐HX 83‐ and 90‐studyMedical and Pediatric Oncology, 2001
- PERMANENT DISABILITIES IN CHILDHOOD SURVIVORS OF LANGERHANS CELL HISTIOCYTOSISPediatric Hematology and Oncology, 2000
- A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans' Cell Histiocytosis Study Group.Archives of Disease in Childhood, 1996
- Treatment strategy for disseminated langerhans cell histiocytosisMedical and Pediatric Oncology, 1994
- Langerhans cell histiocytosis in childhood: Results from the Italian cooperative AIEOP‐CNR‐H.X '83 studyMedical and Pediatric Oncology, 1993
- Quality of survival in histiocytosis X: A southwest oncology group studyMedical and Pediatric Oncology, 1980